Biogen's anti-LINGO-1 mAb fails Phase II test

Biogen Inc. (NASDAQ:BIIB) fell $36.98 (13%) to $252.86 on Tuesday after reporting that opicinumab ( BIIB033) plus Avonex interferon beta-1a missed the primary endpoint vs. placebo plus Avonex in

Read the full 295 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE